063160.KS KSC
CKD Bio Corp.
1W: -0.2%
1M: -9.3%
3M: -5.9%
YTD: -40.2%
1Y: -44.6%
3Y: -45.4%
5Y: -78.2%
₩12,790.00 ($9.51)
+10.00 (+0.08%)
Weekly Expected Move ±2.3%
₩12211
₩12501
₩12790
₩13079
₩13369
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
Balance Sheet Trends
Total Assets
$299.9B
+5.4% ▲
5Y CAGR: +1.1%
Total Liabilities
$172.8B
+12.6% ▲
5Y CAGR: +8.5%
Shareholders Equity
$127.0B
-3.0% ▼
5Y CAGR: -5.5%
Cash & Investments
$1.5B
+28.6% ▲
5Y CAGR: -0.5%
Total Debt
$145.0B
+10.5% ▲
5Y CAGR: +12.7%
Net Debt
$143.5B
+10.3% ▲
Assets vs Liabilities & Equity
Year-over-Year Growth
View Full Balance Sheet
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| — Assets — | |||||
| Cash | $3.5B | $4.7B | $3.6B | $1.1B | $1.4B |
| Short-Term Investments | $69M | $8.1B | $70M | $70M | $70M |
| Cash & ST Investments | $3.5B | $12.7B | $3.7B | $1.2B | $1.5B |
| Net Receivables | $29.9B | $27.5B | $62M | $31.3B | $37.0B |
| Inventory | $70.4B | $78.5B | $69.1B | $80.5B | $96.8B |
| Other Current Assets | $29.9B | $4.0B | $36.7B | $1.2B | $0 |
| Total Current Assets | $104.3B | $123.5B | $111.8B | $115.2B | $136.2B |
| Property, Plant & Equip. | $191.2B | $181.5B | $172.5B | $159.2B | $155.7B |
| Goodwill & Intangibles | $2.8B | $3.8B | $6.1B | $6.5B | $5.6B |
| Long-Term Investments | -$65M | -$6.1B | $2.2B | $1.9B | $2.0B |
| Other Non-Current Assets | $337M | $9.8B | $1.1B | $1.7B | $366M |
| Total Non-Current Assets | $194.2B | $189.1B | $182.0B | $169.3B | $163.6B |
| Total Assets | $298.5B | $312.6B | $293.8B | $284.5B | $299.9B |
| — Liabilities — | |||||
| Accounts Payable | $9.9B | $8.2B | $6.7B | $6.0B | $6.1B |
| Short-Term Debt | $19.3B | $56.3B | $75.8B | $70.1B | $126.7B |
| Deferred Revenue | $14.3B | $244M | $0 | $0 | $749M |
| Other Current Liabilities | $7.4B | $7.0B | $6.6B | $6.6B | $18.5B |
| Total Current Liabilities | $44.3B | $81.6B | $98.6B | $90.7B | $152.0B |
| Long-Term Debt | $89.3B | $80.4B | $69.4B | $59.9B | $17.2B |
| Other Non-Current Liab. | $0 | $1.2B | $1.7B | $2.3B | $2.5B |
| Total Non-Current Liabilities | $92.7B | $83.2B | $72.1B | $62.8B | $20.8B |
| Total Liabilities | $137.0B | $164.8B | $170.8B | $153.5B | $172.8B |
| — Equity — | |||||
| Common Stock | $13.7B | $13.7B | $13.7B | $13.7B | $13.7B |
| Retained Earnings | $118.9B | $103.8B | $77.4B | $86.3B | $82.2B |
| Accumulated OCI | $1.3B | $2.7B | $2.4B | $1.5B | $1.6B |
| Total Stockholders Equity | $161.5B | $147.8B | $123.0B | $131.0B | $127.0B |
| Total Liabilities & Equity | $298.5B | $312.6B | $293.8B | $284.5B | $299.9B |
| — Key Metrics — | |||||
| Total Debt | $109.4B | $138.9B | $146.9B | $131.2B | $145.0B |
| Net Debt | $105.9B | $134.3B | $143.3B | $130.1B | $143.5B |
| Total Investments | $4M | $2.0B | $2.3B | $2.0B | $2.1B |